

Data Sharing Statement

Article Info	Article information: http://dx.doi.org/10.21037/jtd-20-715 .	
Item	Question	Authors' Response (place "-" if not applicable)
1	Would you like to share data collected for your study to others?	Yes
2	If not, would you like to share the reason for your decision?	-
3	What data in particular will be shared?	In clinical practice, adjuvant chemotherapy for completely resected NSCLC using S-1 are promising but problems regarding treatment compliance persist, especially in elderly patients.
4	Any other documents will be share? Such as study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code.	Statistical analysis plan, informed consent form, and clinical study report will also be shared if requested.
5	When will data availability begin?	From the publication date.
6	When will data availability end?	- (Data availability will not end.)
7	To whom will you share the data?	Thoracic surgeons and medical oncologists who are interested in studies of adjuvant chemotherapy for completely resected non-small-cell lung cancer.
8	For what type of analysis or purpose?	For analysis to evaluate the feasibility, safety and usefulness of carboplatin plus S-1 followed by maintenance S-1 as an adjuvant chemotherapy for completely resected non-small-cell lung cancer.
9	How or where can the data/documents be obtained?	Emails could be sent to the address below to obtain the shared data: tahase@fmu.ac.jp
10	Any other restrictions?	We may balance the potential benefits and risks for each request and then provide the data that could be shared.